Matthew A Powell1, Virginia L Filiaci2, Martee L Hensley3, Helen Q Huang2, Kathleen N Moore4, Krishnansu S Tewari5, Larry J Copeland6, Angeles A Secord7, David G Mutch8, Alessandro Santin9, David P Warshal10, Nick M Spirtos11, Paul A DiSilvestro12, Olga B Ioffe13, David S Miller14. 1. Washington University School of Medicine, St Louis, MO. 2. NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY. 3. Memorial Sloan-Kettering Cancer Center, New York, NY. 4. The Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK. 5. University of California, Irvine, Division of Gynecologic Oncology, Orange, CA. 6. Ohio State University, Columbus, OH. 7. Duke Cancer Institute, Durham, NC. 8. Washington University, St Louis, MO. 9. Yale University, Obstetrics and Gynecology, Division of Gynecologic Oncology, New Haven, CT. 10. Cooper Hospital University Medical Center, Camden, NJ. 11. Women's Cancer Center, Las Vegas, NV. 12. Women and Infants Hospital, Providence, RI. 13. University of Maryland Medical Center, Baltimore, MD. 14. UT Southwestern Medical Center at Dallas, Dallas, TX.
Abstract
PURPOSE: This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS). PATIENTS AND METHODS: Adults with chemotherapy-naïve UCS or ovarian carcinosarcoma (OCS) were randomly assigned to PC or PI with 3-week cycles for 6-10 cycles. With 264 events in patients with UCS, the power for an overall survival (OS) hybrid noninferiority design was 80% for a null hazard ratio (HR) of 1.2 against a 13% greater death rate on PI with a type I error of 5% for a one-tailed test. RESULTS: The study enrolled 536 patients with UCS and 101 patients with OCS, with 449 and 90 eligible, respectively. Primary analysis was on patients with UCS, distributed as follows: 40% stage I, 6% stage II, 31% stage III, 15% stage IV, and 8% recurrent. Among eligible patients with UCS, PC was assigned to 228 and PI to 221. PC was not inferior to PI. The median OS was 37 versus 29 months (HR = 0.87; 90% CI, 0.70 to 1.075; P < .01 for noninferiority, P > .1 for superiority). The median progression-free survival was 16 versus 12 months (HR = 0.73; P = < 0.01 for noninferiority, P < .01 for superiority). Toxicities were similar, except that more patients in the PC arm had hematologic toxicity and more patients in the PI arm had confusion and genitourinary hemorrhage. Among 90 eligible patients with OCS, those in the PC arm had longer OS (30 v 25 months) and progression-free survival (15 v 10 months) than those in the PI arm, but with limited precision, these differences were not statistically significant. CONCLUSION: PC was not inferior to the active regimen PI and should be standard treatment for UCS.
PURPOSE: This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS). PATIENTS AND METHODS: Adults with chemotherapy-naïve UCS or ovarian carcinosarcoma (OCS) were randomly assigned to PC or PI with 3-week cycles for 6-10 cycles. With 264 events in patients with UCS, the power for an overall survival (OS) hybrid noninferiority design was 80% for a null hazard ratio (HR) of 1.2 against a 13% greater death rate on PI with a type I error of 5% for a one-tailed test. RESULTS: The study enrolled 536 patients with UCS and 101 patients with OCS, with 449 and 90 eligible, respectively. Primary analysis was on patients with UCS, distributed as follows: 40% stage I, 6% stage II, 31% stage III, 15% stage IV, and 8% recurrent. Among eligible patients with UCS, PC was assigned to 228 and PI to 221. PC was not inferior to PI. The median OS was 37 versus 29 months (HR = 0.87; 90% CI, 0.70 to 1.075; P < .01 for noninferiority, P > .1 for superiority). The median progression-free survival was 16 versus 12 months (HR = 0.73; P = < 0.01 for noninferiority, P < .01 for superiority). Toxicities were similar, except that more patients in the PC arm had hematologic toxicity and more patients in the PI arm had confusion and genitourinary hemorrhage. Among 90 eligible patients with OCS, those in the PC arm had longer OS (30 v 25 months) and progression-free survival (15 v 10 months) than those in the PI arm, but with limited precision, these differences were not statistically significant. CONCLUSION: PC was not inferior to the active regimen PI and should be standard treatment for UCS.
Authors: W. G. McCluggage; M. Abdulkader; J. H. Price; P. Kelehan; S. Hamilton; J. Beattie; A. Al-Nafussi Journal: Int J Gynecol Cancer Date: 2000-07 Impact factor: 3.437
Authors: Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe Journal: Gynecol Oncol Date: 2007-09-05 Impact factor: 5.482
Authors: Linda R Duska; Audrey Garrett; Gamal H Eltabbakh; Esther Oliva; Richard Penson; Arlan F Fuller Journal: Gynecol Oncol Date: 2002-06 Impact factor: 5.482
Authors: Amanda N Fader; Dana M Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko K Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M O'Malley; Floor Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim S ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E Schwartz; Alessandro D Santin Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544
Authors: Robert L Hollis; Ian Croy; Michael Churchman; Clare Bartos; Tzyvia Rye; Charlie Gourley; C Simon Herrington Journal: Br J Cancer Date: 2022-06-17 Impact factor: 9.075
Authors: Joseph Gillam; Raghavendra Pillappa; Michael Idowu; Cecelia Boardman; Stephanie A Sullivan; Sadia Sayeed Journal: SAGE Open Med Case Rep Date: 2022-03-05